NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET ...

President Donald Trump campaigned as a champion of free speech, but First Amendment advocates say they've never seen freedom ...

A union for U.S. Agency for International Development contractors is asking a federal judge to intervene in any destruction ...

Regeneron Pharmaceuticals, Inc. obtained a positive opinion for its pipeline candidate, linvoseltamab, from the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human ...

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Earlier in 2019 Sanofi also paid Regeneron $462 million to exit from an immuno-oncology alliance formed in 2015, and in 2017 said they would end discovery research in new antibody drugs.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA ...